ContraFect Corp

22R

Company Profile

  • Business description

    ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its DLA product candidate, exebacase, is currently being studied in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci, and the next product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumannii, and has demonstrated potent in vivo activity against these pathogens, even against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains.

  • Contact

    28 Wells Avenue
    3rd Floor
    YonkersNY10701
    USA

    T: +1 914 207-2300

    E: [email protected]

    https://www.contrafect.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    23

Stocks News & Analysis

stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.
stocks

Chart of the Week: Anthropic’s IPO range sits below our fair value

Our fair value is above the IPO range, but outcomes could differ widely.
stocks

Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released

Several gaming shares are trading at a discount to our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,836.6095.80-1.07%
CAC 408,080.7466.09-0.81%
DAX 4025,463.81272.43-1.06%
Dow JONES (US)49,165.591,032.58-2.06%
FTSE 10010,452.6898.49-0.93%
HKSE22,841.62453.13-1.95%
NASDAQ23,911.90517.98-2.12%
Nikkei 22559,444.21419.930.71%
NZX 50 Index14,247.2517.04-0.12%
S&P 5007,185.87137.76-1.88%
S&P/ASX 2008,730.4091.40-1.04%
SSE Composite Index3,577.6210.21-0.28%

Market Movers